中安科(600654.SH):控股股東自願延長股份限售鎖定期
格隆匯12月25日丨中安科(600654.SH)公佈,公司於2023年12月27日收到控股股東深圳市中恒匯志投資有限公司(簡稱“中恒匯志”)送達的關於延長股份限售鎖定期承諾的函件,中恒匯志自願將其持有公司的限售流通股份鎖定期延長至2024年12月31日。具體內容詳見公司於2023年12月28日在指定信息披露媒體發佈的《關於控股股東自願延長股份限售鎖定期的公吿》。近日,公司收到中恒匯志送達的關於延長股份限售鎖定期承諾的函件,基於對公司未來發展的信心,本着對公司社會公眾股東負責的態度,中恒匯志自願將其持有公司的342,940,464股限售流通股股票鎖定期延長至2025年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.